CaroGen Corporation, a clinical-stage biotechnology company advancing novel immunotherapies for chronic infectious diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has authorized the company to proceed with its first-in-human clinical study under Investigational New Drug (IND) Application No. 31717 for CARG-201